protein

Recombinant Human p53

MBS143809

0.002 mg

265 USD

Recombinant Protein

Recombinant Human p53

p53

p53 Human; p53 Protein Human Recombinant; Cellular tumor antigen p53; Tumor suppressor p53; Phosphoprotein p53; Antigen NY-CO-13; TP53; P53; LFS1; TRP53; FLJ92943

cellular tumor antigen p53 isoform a; Cellular tumor antigen p53; cellular tumor antigen p53; antigen NY-CO-13; mutant tumor protein 53; p53 tumor suppressor; phosphoprotein p53; transformation-related protein 53; tumor protein p53; Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53

p53

TP53; TP53; P53; BCC7; LFS1; TRP53; P53

P53_HUMAN

E Coli

393

purified human p53 in 50mM Tris-HCl, pH-7.5 and 10mM L-glutathione (reduced). Sterile Filtered clear solution.

0.1 mg/ml

For long term storage store at -20 degree C. Avoid freeze/thaw cycles.

RECOMBINANT & NATURAL PROTEINS; Recombinant Proteins; p53

Description: p53 Human Recombinant full length produced in E Coli is a non-glycosylated, polypeptide chain having a total Mw of 81kDa. p53 Human Recombinant is fused to GST tag and purified by proprietary chromatographic techniques. Introduction: Tumor protein p53 responds to various cellular stresses by regulating target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 is a tumor suppressor gene expressed in a wide variety of tissue types and is involved in regulating cell growth, replication, and apoptosis. p53 is a DNA-binding protein containing transcription activation, DNA-binding & oligomerization domains. p53 binds to mdm2, SV40 T antigen and human papilloma virus E6 protein p53 senses DNA damage and possibly facilitating repair. p53 protein is a transcription factor which is encoded in humans by the TP53 gene. Alterations of TP53 occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. p53 mutants that often occur in many different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Mutation involving p53 is found in a wide variety of malignant tumors, including breast, ovarian, bladder, colon, lung, and melanoma. The p53 expression in normal cells is low and in an assortment of transformed cell lines is high, which may contribute to transformation and malignancy. Multiple p53 variants encode distinct isoforms, which can regulate p53 transcriptional activity. p53's significance in multicellular organisms is in cell cycle regulation therefore it functions as a tumor suppressor that is involved in preventing cancer. p53's role in conserving stability by preventing genome mutation has earned it descriptions such as "the guardian of the genome," "the guardian angel gene," and the "master watchman. The name p53 refers to its evident molecular mass: it migrates as a 53kDa protein on SDS-PAGE. However, based on calculations from its amino acid residues, p53's mass is in fact only 43.7kDa. This difference is attributed to the high number of proline residues in the protein which slow its migration on SDS-PAGE, consequently making it appear larger than it actually is.

120407068

NP_000537.3

NM_000546.5

P04637

24,401 Da

AMPK Signaling Pathway (198868); Activation Of BH3-only Proteins Pathway (105658); Activation Of NOXA And Translocation To Mitochondria Pathway (105660); Activation Of PUMA And Translocation To Mitochondria Pathway (105661); Alzheimers Disease Pathway (672448); Amyotrophic Lateral Sclerosis (ALS) Pathway (920975); Amyotrophic Lateral Sclerosis (ALS) Pathway (83099); Amyotrophic Lateral Sclerosis (ALS) Pathway (511); Apoptosis Pathway (198797); Apoptosis Pathway (83060)

This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013]

p53: a transcription factor and major tumor suppressor that plays a major role in regulating cellular responses to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis. More than 50 percent of human tumors contain a mutation or deletion of the TP53 gene. p53 is modified post-translationally at multiple sites. DNA damage induces phosphorylation of p53 at S15, S20 and S37, reducing its interaction with the oncoprotein MDM2. MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation. Phosphorylated by many kinases including Chk2 and Chk1 at S20, enhancing its tetramerization, stability and activity. The phosphorylation by CAK at S392 is increased in human tumors and has been reported to influence the growth suppressor function, DNA binding and transcriptional activation of p53. Phosphorylation of p53 at S46 regulates the ability of p53 to induce apoptosis. The acetylation of p53 appears to play a positive role in the accumulation of p53 during the stress response. Following DNA damage, p53 becomes acetylated at K382, enhancing its binding to DNA. Deacetylation of p53 can occur through interaction with SIRT1, a deacetylase that may be involved in cellular aging and the DNA damage response. p53 regulates the transcription of a set of genes encoding endosomal proteins that regulate endosomal functions. These include STEAP3 and CHMP4C, which enhance exosome production, and CAV1 and CHMP4C, which produce a more rapid endosomal clearance of the EGFR from the plasma membrane. DNA damage regulates a p53-mediated secretory pathway, increasing the secretion of some proteins such as Hsp90, SERPINE1, SERPINB5, NKEF-A, and CyPA, and inhibiting the secretion of others including CTSL and IGFBP-2. Two alternatively spliced human isoforms have been reported. Isoform 2 is expressed in quiescent lymphocytes. Seems to be non-functional. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. Protein type: DNA-binding; Motility/polarity/chemotaxis; Activator; Transcription factor; Nuclear receptor co-regulator; Tumor suppressor. Chromosomal Location of Human Ortholog: 17p13.1. Cellular Component: PML body; transcription factor TFIID complex; protein complex; nuclear matrix; mitochondrion; endoplasmic reticulum; replication fork; cytosol; nucleoplasm; nuclear body; mitochondrial matrix; cytoplasm; nuclear chromatin; nucleolus; chromatin; nucleus. Molecular Function: identical protein binding; protease binding; protein phosphatase 2A binding; zinc ion binding; p53 binding; protein N-terminus binding; receptor tyrosine kinase binding; protein phosphatase binding; transcription factor binding; protein kinase binding; histone acetyltransferase binding; protein binding; copper ion binding; histone deacetylase regulator activity; enzyme binding; DNA binding; protein heterodimerization activity; ubiquitin protein ligase binding; chaperone binding; damaged DNA binding; chromatin binding; transcription factor activity; ATP binding. Biological Process: viral reproduction; positive regulation of apoptosis; multicellular organismal development; positive regulation of transcription, DNA-dependent; T cell differentiation in the thymus; gastrulation; determination of adult life span; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; response to antibiotic; regulation of apoptosis; cellular response to glucose starvation; protein localization; negative regulation of neuroblast proliferation; base-excision repair; transforming growth factor beta receptor signaling pathway; cerebellum development; protein complex assembly; cell cycle arrest; ER overload response; response to X-ray; somitogenesis; release of cytochrome c from mitochondria; chromatin assembly; cell aging; circadian behavior; rRNA transcription; positive regulation of peptidyl-tyrosine phosphorylation; negative regulation of fibroblast proliferation; negative regulation of DNA replication; embryonic organ development; positive regulation of transcription from RNA polymerase II promoter; regulation of mitochondrial membrane permeability; negative regulation of transcription, DNA-dependent; regulation of tissue remodeling; negative regulation of apoptosis; G1 DNA damage checkpoint; transcription from RNA polymerase II promoter; DNA damage response, signal transduction by p53 class mediator; apoptosis; negative regulation of transcription from RNA polymerase II promoter; response to salt stress; entrainment of circadian clock by photoperiod; positive regulation of protein oligomerization; negative regulation of cell proliferation; positive regulation of histone deacetylation; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; regulation of transcription, DNA-dependent; T cell proliferation during immune response; double-strand break repair; positive regulation of neuron apoptosis; response to gamma radiation; cell differentiation; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; protein tetramerization; mitochondrial DNA repair; Notch signaling pathway; in utero embryonic development; B cell lineage commitment; multicellular organism growth; cell proliferation; neuron apoptosis; T cell lineage commitment; negative regulation of helicase activity; protein import into nucleus, translocation; nucleotide-excision repair; Ras protein signal transduction; DNA strand renaturation; negative regulation of cell growth; negative regulation of transforming growth factor beta receptor signaling pathway; blood coagulation; response to DNA damage stimulus. Disease: Papilloma Of Choroid Plexus; Pancreatic Cancer; Nasopharyngeal Carcinoma; Breast Cancer; Li-fraumeni Syndrome 1; Osteogenic Sarcoma; Colorectal Cancer; Glioma Susceptibility 1; Adrenocortical Carcinoma, Hereditary; Basal Cell Carcinoma, Susceptibility To, 7; Hepatocellular Carcinoma

0.002 mg

265 USD

0.005 mg

365

0.01 mg

610